entertainment -WSS

entertainment

author：entertainment 2025-10-03 00:40:14 - browse：7536

Several amyloid plaques forming between neurons in a brain — Amyloid plaques forming between neurons. Adobe

The Food and Drug Administration on Thursday granted full approval to the first therapy for Alzheimer’s disease clearly shown to slow the cognitive decline associated with the disease — a milestone in treatment, even if the benefits are modest.

The drug, called Leqembi, was developed by Eisai, the Japanese pharmaceutical company, and sold in partnership with Biogen. It previously secured conditional approval in January. The FDA’s decision will broaden patient access to the drug under the Medicare program and is likely to boost sales, even as Leqembi’s benefits and safety risks continue to be a source of debate.

Leqembi’s full, or traditional, approval was supported by results of a large clinical trial in which the drug slowed the rate of cognitive and functional decline by 27% compared to a placebo. Leqembi also beat placebo on a series of secondary measures of Alzheimer’s, and it had a dramatic effect on clearing toxic brain plaques called beta-amyloid, which play a role in the progression of the disease.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： Takeda, Janssen join wearable maker to measure scratching

focus

hotspot

WSS

EF3 tornado rips through North Carolina amid extreme weather nationwide

J&J to emphasize cancer drugs, stop much of its vaccine research

J&J to emphasize cancer drugs, stop much of its vaccine research

7 more heat

Key lawmaker blasts Congress’ efforts on addiction: ‘Shame on us’

Readout Newsletter: The latest in Pfizer, Moderna, and Sanofi

hotspot

entertainment

hotspot

Medicare proposal to cover medical devices draws a mixed reaction

Indian pharmaceutical industry in denial over drug

Psychedelics group wrestles with new pharma identity

Mayo Clinic plans $5B tech

Malaria cases in Florida and Texas: Here’s what you need to know

What to do when lifesaving products contribute to climate change

Psychedelics group wrestles with new pharma identity

Fetal surgery at risk from Dobbs and new abortion restrictions

Medical records are filled with copy

Diagnostic tests are hitting their mathematical limits

Wikipedia

Fetal surgery at risk from Dobbs and new abortion restrictions

Jury awards Florida girl burned by McDonald's Chicken McNugget $800,000 in damages

CDC director unscathed in first congressional testimony

Readout Newsletter: The latest in Pfizer, Moderna, and Sanofi

U.K. Biobank has 500,000 peoples' genome sequences available

With clinical trial data readouts, here's how to spot spin

knowledge

focus

hotspot

explore